Menu
Sign In Search Podcasts Charts Entities Add Podcast API Pricing
Podcast Image

CME in Minutes: Education in Oncology & Hematology

Miguel-Angel Perales, MD - Shifting Gears in Treating Relapsed and Refractory Indolent B-Cell Lymphomas: Where Do CAR T Cell Therapies Stand in FL and CLL/SLL?

03 Jul 2023

Description

Please visit answersincme.com/FSV860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in hematologic cancer discusses the use of chimeric antigen receptor (CAR) T cell therapies in B-cell lymphoma. Upon completion of this activity, participants should be better able to: Recognize the clinical rationale for using chimeric antigen receptor (CAR) T cell therapies for relapsed/refractory indolent follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL); Describe the clinical profiles of approved and emerging CD19-directed CAR T cell therapies for relapsed/refractory indolent FL and CLL/SLL; and Outline clinical considerations for the use of CD19-directed CAR T cell therapies for relapsed/refractory indolent FL and CLL/SLL.

Audio
Featured in this Episode

No persons identified in this episode.

Transcription

No transcription available yet

Help us prioritize this episode for transcription by upvoting it.

0 upvotes
🗳️ Sign in to Upvote

Popular episodes get transcribed faster

Comments

There are no comments yet.

Please log in to write the first comment.